These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 9306349)
41. Ten years of treatment with tacrolimus is related to an excellent renal function, allowing monotherapy in a large proportion of cases: unicentric results of the tacrolimus versus cyclosporine A European Multicentric Study in kidney transplant patients. Morales JM; Andrés A; Dominguez-Gil B; Arriola M; Gutiérrez MJ; Hernández E; Ortuño T; Praga M Transplant Proc; 2005 Nov; 37(9):3738-42. PubMed ID: 16386523 [TBL] [Abstract][Full Text] [Related]
42. De novo use of everolimus with elimination or minimization of cyclosporine in renal transplant recipients. Novoa PA; Grinyó JM; Ramos FJ; Errasti P; Franco A; Aldana G; Pefaur J; Marti-Cuadros AM; Otero AB; Saval N; Oppenheimer F Transplant Proc; 2011 Nov; 43(9):3331-9. PubMed ID: 22099791 [TBL] [Abstract][Full Text] [Related]
43. Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversible. Sommerer C; Hergesell O; Nahm AM; Schwenger V; Waldherr R; Andrassy K; Zeier M Nephron; 2002 Oct; 92(2):339-45. PubMed ID: 12218312 [TBL] [Abstract][Full Text] [Related]
44. The impact of mycophenolate mofetil versus azathioprine as adjunctive therapy to cyclosporine on the rates of renal allograft loss due to glomerular disease recurrence. Pham PT; Pham PC Nephrol Dial Transplant; 2012 Jul; 27(7):2965-71. PubMed ID: 22207327 [TBL] [Abstract][Full Text] [Related]
45. [Acute rejection in cadaveric renal transplantation under cyclosporine based therapy. Analysis of the risk factors and its influence on chronic dysfunction]. Mota A Acta Med Port; 2004; 17(1):8-14. PubMed ID: 15636737 [TBL] [Abstract][Full Text] [Related]
46. Complete replacement of methylprednisolone by azathioprine in cyclosporine-treated primary cadaveric renal transplant recipients. Kupin W; Venkat KK; Oh HK; Dienst S Transplantation; 1988 Jan; 45(1):53-5. PubMed ID: 3276062 [TBL] [Abstract][Full Text] [Related]
47. The effect of felodipine on renal function and blood pressure in cyclosporin-treated renal transplant recipients during the first three months after transplantation. Madsen JK; Sørensen SS; Hansen HE; Pedersen EB Nephrol Dial Transplant; 1998 Sep; 13(9):2327-34. PubMed ID: 9761517 [TBL] [Abstract][Full Text] [Related]
48. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Min DI; Perry PJ; Chen HY; Hunsicker LG Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147 [TBL] [Abstract][Full Text] [Related]
49. Steroid and azathioprine versus steroid, cyclosporine, and azathioprine therapies in primary haplo-identical living donor kidney transplantation: twenty-year experience. Gheith OA; Bakr MA; Fouda MA; Shokeir AA; Bayoumy A; Sobh M; Ghoneim M Iran J Kidney Dis; 2008 Jan; 2(1):34-9. PubMed ID: 19367007 [TBL] [Abstract][Full Text] [Related]
50. Triple therapy in cadaveric renal transplantation: role of induction cyclosporine and targeted levels to avoid rejection. Khauli RB; Wilson JM; Baker SP; Valliere SA; Lovewell TD; Stoff JS J Urol; 1995 Jun; 153(6):1805-9; discussion 1810. PubMed ID: 7752322 [TBL] [Abstract][Full Text] [Related]
51. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Webster A; Woodroffe RC; Taylor RS; Chapman JR; Craig JC Cochrane Database Syst Rev; 2005 Oct; (4):CD003961. PubMed ID: 16235347 [TBL] [Abstract][Full Text] [Related]
52. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. Abramowicz D; Del Carmen Rial M; Vitko S; del Castillo D; Manas D; Lao M; Gafner N; Wijngaard P; J Am Soc Nephrol; 2005 Jul; 16(7):2234-40. PubMed ID: 15917338 [TBL] [Abstract][Full Text] [Related]
53. Misoprostol in renal transplant recipients: a prospective, randomized, controlled study on the prevention of acute rejection episodes and cyclosporin A nephrotoxicity. Pouteil-Noble C; Chapuis F; Berra N; Hadj-Aissa A; Lacavalerie B; Lefrançois N; Martin X; Touraine JL Nephrol Dial Transplant; 1994; 9(5):552-5. PubMed ID: 8090337 [TBL] [Abstract][Full Text] [Related]
54. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years. Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230 [TBL] [Abstract][Full Text] [Related]
55. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety. Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241 [TBL] [Abstract][Full Text] [Related]
56. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study. Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040 [TBL] [Abstract][Full Text] [Related]
57. Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. Aumente MD; Arizón JM; Segura J; López A; Albornoz R; Cárdenas M; Segura C Transplant Proc; 2005 Nov; 37(9):4014-7. PubMed ID: 16386613 [TBL] [Abstract][Full Text] [Related]
58. Cyclosporin A withdrawal in live related renal transplantation: long-term results. Dubey D; Kumar A; Srivastava A; Mandhani A; Sharma AP; Gupta A; Sharma RK Clin Transplant; 2001 Apr; 15(2):136-41. PubMed ID: 11264641 [TBL] [Abstract][Full Text] [Related]